Toyota|$17.88 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.39 (¥4,016)+1.41%▲ (in JPY terms)
SoftBank|$29.29 (¥4,634)+1.76%▲ (in JPY terms)
MUFG|$21.71 (¥3,434)+2.48%▲ (in JPY terms)
Keyence|$513.83 (¥81,280)+0.46%▲ (in JPY terms)
Nintendo|$55.13 (¥8,720)+0.46%▲ (in JPY terms)
NTT|$1.11 (¥176)-0.79%▼ (in JPY terms)
Takeda|$40.07 (¥6,339)+0.46%▲ (in JPY terms)
Tokyo Electron|$64.48 (¥10,200)+1.14%▲ (in JPY terms)
Recruit|$120.02 (¥18,985)+0.98%▲ (in JPY terms)
ITOCHU|$14.61 (¥2,311)+0.57%▲ (in JPY terms)
Honda|$11.43 (¥1,808)+0.22%▲ (in JPY terms)
Shin-Etsu|$37.38 (¥5,913)+0.75%▲ (in JPY terms)
Tokio Marine|$3.53 (¥559)+2.63%▲ (in JPY terms)
Fast Retailing|$476.47 (¥75,370)+0.01%▲ (in JPY terms)
Toyota|$17.88 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.39 (¥4,016)+1.41%▲ (in JPY terms)
SoftBank|$29.29 (¥4,634)+1.76%▲ (in JPY terms)
MUFG|$21.71 (¥3,434)+2.48%▲ (in JPY terms)
Keyence|$513.83 (¥81,280)+0.46%▲ (in JPY terms)
Nintendo|$55.13 (¥8,720)+0.46%▲ (in JPY terms)
NTT|$1.11 (¥176)-0.79%▼ (in JPY terms)
Takeda|$40.07 (¥6,339)+0.46%▲ (in JPY terms)
Tokyo Electron|$64.48 (¥10,200)+1.14%▲ (in JPY terms)
Recruit|$120.02 (¥18,985)+0.98%▲ (in JPY terms)
ITOCHU|$14.61 (¥2,311)+0.57%▲ (in JPY terms)
Honda|$11.43 (¥1,808)+0.22%▲ (in JPY terms)
Shin-Etsu|$37.38 (¥5,913)+0.75%▲ (in JPY terms)
Tokio Marine|$3.53 (¥559)+2.63%▲ (in JPY terms)
Fast Retailing|$476.47 (¥75,370)+0.01%▲ (in JPY terms)

2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for combination therapy with pembrolizumab for resectable muscle-invasive bladder cancer that is unsuitable for cisplatin, providing a new treatment option as adjuvant therapy before and after surgery.”

by

2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for combination therapy with pembrolizumab for resectable muscle-invasive bladder cancer that is unsuitable for cisplatin, providing a new treatment option as adjuvant therapy before and after surgery.”

Tags: Astellas Pharma Inc.JP3942400007

コメントする

Contact